NCT05578443招募中2 期
Efficacy, Safety and Response Predictors of Astragalus Membranaceus on the Improvement of Cognitive Function in Mild-to-Moderate Alzheimer's Disease: a Randomized Controlled Trial Protocol
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 66
- 试验地点
- 1
- 主要终点
- The primary efficacy outcome measure will be the absolute change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Chinese version score between baseline and week 48.
研究概览
简要总结
Alzheimer's disease (AD), the most common cause of dementia, is characterized by cognitive impairment, mental and behavioural abnormalities, and social dysfunction. Current treatments can only delay the progression of AD, not cure it completely. In vitro studies have shown that Astragalus has toxic effects such as anti-hypoxia injury of nerve cells, anti-free radical damage, anti-excitatory amino acids, etc. It can be used to expand cerebral vessels, increase cerebral blood flow, improve cerebral microcirculation, protect brain cells, and repair damaged brain cells. However, the clinical effects of add-on Astragalus in improving cognition in these patients remain unclear. Therefore, this pragmatic clinical trial aims to determine the efficacy and safety of add-on Astragalus in improving cognition in patients with AD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The inclusion criteria will be as follows:
- •Male or female aged ≥50 years and ≤85 years
- •Memory loss for at least 6 months, with a progressive worsening trend Patients with mild or moderate disease degree, that is, the total score of MMSE: 14 points < total score of MMSE <24 points, 0.5≤CDR≤2 points, and the total score of HAMD (24-item version) ≤20 points
- •Brain magnetic resonance imaging shows the degree of hippocampal atrophy is greater than or equal to grade 1
- •The modified Hachinski Ischemia Scale (m-HIS) score was < 4 points
- •The criteria described by the diagnostic and statistical manual of mental disorder-V for the diagnosis of dementia comply with the National Institute on Aging - Alzheimer's Association "Very likely AD" (National Institute of Aging-Alzheimer's Association, 2011).
- •There are no obvious positive signs in nervous system examination;
- •The subjects have the ability of reading, writing and communication, have a stable caregiver, accompany to attend the visit.
- •The basic treatment of AD before enrollment remained unchanged, and if long-term users needed to use it steadily for more than 4 weeks before randomization,the dose was kept as stable as possible during the study. Such drugs include: cholinesterase inhibitors.
排除标准
- •The exclusion criteria will be as follows:
- •MRI showed significant focal lesions, including one of the following: a. There were more than 2 infarcts with a diameter greater than 2cm; b. Infarcts in key areas such as the thalamus, hippocampus, entorhinal cortex, parorhinal cortex, angular gyrus, cortex, and other subcortical gray matter nuclei; c. White matter lesion Fazekas Scale ≥3
- •Patients who have taken other Chinese medicine preparations in the past three months
- •Allergy or contraindication of astragalus
- •There are other neurological diseases that can cause brain dysfunction or cognitive impairment; Mental and neurological retardation is present; Presence of malignant tumor
- •The modified Hachinski Ischemia Scale (m-HIS) score was ≥ 4 points. Patients who refuse or have MRI or EEG contraindications (pacemakers, coronary and peripheral arterial stents, Metal implants, claustrophobia, or severe visual or hearing impairment), refusing to draw blood
- •Pregnant or lactating patients;
- •Patients who have participated in other clinical studies within the past 3 months
研究组 & 干预措施
10g Astragalus membranaceus
Experimental
干预措施: 10g Astragalus (Drug)
10g Astragalus membranaceus
Experimental
干预措施: Routine treatment (Behavioral)
Routine treatment
Experimental
干预措施: Routine treatment (Behavioral)
20g Astragalus membranaceus
Experimental
干预措施: Routine treatment (Behavioral)
20g Astragalus membranaceus
Experimental
干预措施: 20g Astragalus (Drug)
结局指标
主要结局
The primary efficacy outcome measure will be the absolute change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale, Chinese version score between baseline and week 48.
时间窗: Participants will be followed up for 48 weeks after baseline.
The Alzheimer's Disease Assessment Scale-Cognitive Subscale, Chinese version scale scores range from 0 to 75, with higher scores indicating better.
次要结局
- The absolute change in the VP300 between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Rey-Osterrieth Complex Figure Test [ROCF] recall score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline)
- The absolute scores change in the Hamilton Anxiety Scale score between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the P300 between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the isotropic volume fraction between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Trail Making Test-A score between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the blood pressure between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the level of plasma β-amyloid42 (ng/ml) between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in volume, between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Clock-Drawing Test score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline)
- The absolute scores change in the Digit Span Forward score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Trail Making Test-B score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the ROCF-copy score between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Digit Span Backward score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Verbal Fluency Test score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute scores change in the Hamilton Depression Scale score between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the level of plasma β-amyloid40 (ng/ml) between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the level of plasma glial fibrillary acidic protein (ng/ml) between baseline and week 48(Participants will be followed up for 48 weeks after baseline)
- The absolute change in the level of plasma neurofilament light chain (ng/ml) between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the MMN between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in surface area between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the level of plasma hyper-phosphorylated tau-181 (ng/ml) between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the neurite density index between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in the orientation dispersion index between baseline and week 48(Participants will be followed up for 48 weeks after baseline.)
- The absolute change in thickness, between baseline and week 48.(Participants will be followed up for 48 weeks after baseline.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy, Safety of Astragalus Membranaceus in Mild-to-Moderate Alzheimer's DiseaseAlzheimer DiseaseNCT06694597Fujian Medical University Union Hospital76
Unknown
不适用
The Safety and Scientific Validity of Low-dose Whole Brain Radiotherapy in Alzheimer's Disease.Alzheimer DiseaseNCT04203121Kyung Hee University Hospital at Gangdong10
已完成
4 期
Memantine for Agitation and Aggression in Severe Alzheimer's DiseaseAlzheimer's DiseaseNCT00401167Sunnybrook Health Sciences Centre31
已完成
不适用
Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise TrainingAlzheimer's DiseaseNCT02968875University Hospital Center of Martinique54
招募中
不适用
Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.Alzheimer DiseaseMild Cognitive ImpairmentSubjective Cognitive DeclineNCT03851523Barcelonabeta Brain Research Center, Pasqual Maragall Foundation400